

The Annual Report was presented
and adopted at the Annual General
Meeting of the Company on
20 June 2023

Søren Justesen

Altasciences HoldCo A/S

Annual Report 2022

Tuborg Havnevej 19
DK-2900 Hellerup

CVR-no. 41 12 03 20

Content

	Page
Management's Statement.....	3
Independent Auditor's Report.....	4
General information about the Company.....	6
Management's Review.....	7
Income statement for the financial year 1 January - 31 December.....	8
Balance sheet at 31 December.....	9
Statement of changes in equity.....	10
Notes.....	11

Management's Statement

The Executive Management and Board of Directors have today considered and adopted the Annual Report of Altasciences HoldCo A/S for the financial year 1 January – 31 December 2022.

The Annual Report has been prepared in accordance with the Danish Financial Statements Act.

In our opinion, the Financial Statements give a true and fair view of the Company's financial position at 31 December 2022 and of the result of the Company's operations for the financial year 1 January - 31 December 2022.

In our opinion, Management's Review includes a true and fair view of the matters included in the Management's Review.

We recommend that the Annual Report be adopted at the Annual General Meeting.

Hellerup, 20 June 2023

Executive Management

Abhijeet Jayant Lele

Board of Directors

Claus Hansen
Chair

Abhijeet Jayant Lele

Søren Justesen

Jonathan Lee Levy

Independent Auditor's Report

To the shareholder of Altasciences HoldCo A/S

In our opinion, the Financial Statements give a true and fair view of the financial position of the Company at 31 December 2022, and of the results of the Company's operations for the financial year 1 January - 31 December 2022 in accordance with the Danish Financial Statements Act.

We have audited the Financial Statements of Altasciences HoldCo A/S for the financial year 1 January - 31 December 2022, which comprise income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies ("financial statements").

Basis for Opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the *Auditor's Responsibilities for the Audit of the Financial Statements* section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountants' International Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the IESBA Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Statement on Management's Review

Management is responsible for Management's Review.

Our opinion on the financial statements does not cover Management's Review, and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read Management's Review and, in doing so, consider whether Management's Review is materially inconsistent with the financial statements or our knowledge obtained during the audit, or otherwise appears to be materially misstated.

Moreover, it is our responsibility to consider whether Management's Review provides the information required under the Danish Financial Statements Act.

Based on the work we have performed, in our view, Management's Review is in accordance with the Financial Statements and has been prepared in accordance with the requirements of the Danish Financial Statements Act. We did not identify any material misstatement in Management's Review.

Management's Responsibilities for the Financial Statements

Management is responsible for the preparation of Financial Statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, Management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting in preparing the financial statements unless Management either intends to liquidate the Company or cease operations, or has no realistic alternative to do so.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management.
- Conclude on the appropriateness of Management's use of the going concern basis of accounting in preparing the financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and contents of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Hellerup, 20 June 2023

PricewaterhouseCoopers

Statsautoriseret Revisionspartnerselskab

CVR-NR.: 33 77 12 31

Tue Stensgård Sørensen
State Authorized Public Accountant
mne32200

Elife Savas
State Authorized Public Accountant
mne34453

General information about the Company

Company	Altasciences HoldCo A/S Tuborg Havnevej 19 2900 Hellerup Denmark Phone: 3527 6500 Date of foundation: January 28, 2020 CVR-no.: 41 12 03 20 Financial year: 1 January - 31 December Municipality of domicile: Gentofte
Executive Management	Abhijeet Jayant Lele
Board of Directors	Claus Hansen (Chair) Abhijeet Jayant Lele Søren Justesen Jonathan Lee Levy
Auditor	PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab Strandvejen 44 2900 Hellerup CVR-no: 33 77 12 31

Management's Review

The main activities of the Company

Altasciences HoldCo A/S is 100% owned by Novo Holdings A/S, Hellerup.

Altasciences HoldCo A/S purpose is to buy and own shares.

The Company has invested in the Altasciences Group via Amalthea Acquisition Holdings LP.

Financial results

The Company's financial result for financial year is a loss of TDKK 40. The Company's equity at 31 December 2022 amounts to TDKK 1,951,571.

Events after the balance sheet date

There have been no events after the balance sheet date which would have a significant impact on the assessment of Company' financial position as of 31 December 2022.

Income Statement for the financial year 1 January - 31 December

TDKK	Note	2022	2021
Other operating costs		<u>-43</u>	<u>-48</u>
Gross result		-43	-48
Realized gain on investments in subsidiaries		0	1
Realized loss on investments in subsidiaries		0	-1,205
Other financial income		12	1,120
Other financial expenses	4	<u>-20</u>	<u>-54</u>
Result before tax		-51	-186
Tax on net result for the year	5	<u>11</u>	<u>-224</u>
Loss for the year		<u>-40</u>	<u>-410</u>
Proposed distribution of the result:			
Proposed dividend		0	0
Extraordinary dividend		0	77,450
Retained earnings		<u>-40</u>	<u>-77,860</u>
		<u>-40</u>	<u>-410</u>

Balance sheet at 31 December

TDKK	Note	2022	2021
Assets			
Investments in subsidiaries		1,951,543	1,951,543
Total non-current assets		1,951,543	1,951,543
Tax receivables		14	0
Intercompany receivables		223	211
Total receivables		237	211
Cash and bank balances		118	385
Total current assets		355	596
Total assets		1,951,898	1,952,139
Equity and liabilities			
Share capital		400	400
Retained earnings		1,951,171	1,951,211
Total equity		1,951,571	1,951,611
Deferred tax		5	2
Total non-current liabilities		5	2
Tax payables		0	222
Intercompany payables		279	262
Trade payables		43	42
Total current liabilities		322	526
Total liabilities		327	528
Total equity and liabilities		1,951,898	1,952,139
Accounting policies	1		
Events after the balance sheet date	2		
Employees	3		
Contingent liabilities	6		
Consolidated financial statements	7		

Statement of changes in equity

TDKK	Share capital	Retained earnings	Total
2021			
Equity 1 January	400	-256	144
Group Contribution 23 February	-	2,562	2,562
Group Contribution 25 March	-	2,026,765	2,026,765
Extraordinary dividend	-	-77,450	-77,450
Result for the year	-	-410	-410
Equity 31 December	400	1,951,211	1,951,611
2022			
Equity 1 January	400	1,951,211	1,951,611
Result for the year	-	-40	-40
Equity 31 December	400	1,951,171	1,951,571

Share capital consist of 400,000 shares with a value of DKK 1 per share.

Notes

Note 1 – Accounting policies

The Annual Report of Altasciences HoldCo A/S has been prepared in accordance with the requirement of the Danish Financial Statements Act reporting class B with elements from reporting class C. The accounting policies are unchanged compared to last year.

The Annual Report is presented in TDKK.

Translation of foreign currencies

Foreign currency transactions are translated using the exchange rates prevailing at the transactions dates. Foreign exchange gains and losses, resulting from the settlement of such transactions and from the translation at year-end exchange rates of monetary assets and liabilities, are recognised in the income statement.

Other operating costs

Other operating costs comprises of operating costs related to the company's activities.

Result of shares in subsidiaries

Result of shares in subsidiaries includes value adjustments and dividends received, is included in the profit and loss in the year the dividend is distributed.

Other financial income

Financial income comprise interest and realised and unrealised foreign currency translations adjustments and other financial income. Interests is included in the profit and loss with the amount related to the current financial year, regardless of due date.

Other financial costs

Financial costs comprise interest and realised and unrealised foreign currency translations adjustments and other financial costs. Interests is included in the profit and loss with the amount related to the current financial year, regardless of due date.

Income taxes

The tax expense for the period comprises current and deferred tax and interests.

The company is jointly taxed with Novo Holdings A/S. The tax for the individual companies is allocated in full on the basis of the expected taxable income.

Financial assets

Investments in subsidiaries are recognised at cost price. If the costs exceeds the recoverable amount, the carrying amount is written down to recoverable amount.

Tax and deferred tax

Tax payable/receivable includes tax payable computed based on the expected taxable income for the year.

Deferred tax is measured according to the balance sheet method for all temporary differences between the carrying amount and tax value of assets and liabilities, where the tax value of the assets is calculated based on the planned use of each asset. Deferred tax assets, including the tax value of tax loss carryforwards, are included in the balance sheet at the value at which the asset at which the asset can be expected to be realized, either by off-setting towards the deferred tax liabilities or as net tax assets.

Financial assets

Investments in subsidiaries are recognised at cost price. If the costs exceeds the recoverable amount, the carrying amount is written down to recoverable amount.

Receivables

Receivables are measured at amortized cost.

An impairment loss are recognized if there is objective evidence that a receivable or a group of receivables is impaired.

Financial liabilities

Financial liabilities are stated at amortised cost unless specifically mentioned otherwise.

Note 2 Events after the balance sheet date

There have been no events after the balance sheet date which would have a significant impact on the assessment of Company' financial position as of 31 December 2022.

TDKK	2022	2021
Note 3 Number of employees		
Average number of employees in the financial year	<u>0</u>	<u>0</u>

The management do not receive remuneration.

Note 4 Other financial expenses

Interest expenses, intercompany	17	25
Other financial expenses	<u>3</u>	<u>29</u>
Total other financial expenses	<u>20</u>	<u>54</u>

Note 5 Tax on net result for the year

Current tax net profit for the year	-14	222
Deferred tax on net profit for the year	<u>3</u>	<u>2</u>
Total tax on net result for the year	<u>-11</u>	<u>224</u>

Note 6 Contingent liabilities

The Company is jointly taxed with the Danish companies in the Group, which are included in the joint taxation of the parent company, Novo Holdings A/S. The joint taxation also covers withholding taxes in the form of dividend tax, royalty tax and interest tax. The Danish companies are jointly and individually liable for the joint taxation. Any subsequent adjustments to income taxes and withholding taxes may lead to a larger liability.

Note 7 Consolidated financial statements

Altasciences HoldCo A/S is a wholly owned subsidiary of Novo Holdings A/S and pursuant to the Danish Financial Statements Act paragraph 112, 1, 2) included in the consolidated financial statements of Novo Nordisk Fonden, registration number 10 58 29 89, Tuborg Havnevej 19, DK-2900 Hellerup.